Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Gestational diabetes mellitus (GDM) is one of the prevalent adverse conditions among pregnant women which needs delicate monitoring and control. GDM is a state in which the pregnant women’s blood glucose level exceeds the normal range. Our goal was to determine the best therapeutic method to control the blood glucose level among GDM patients by comparing of the efficacy between two Insulin consisting, Novo-rapid $+$ Levemir Insulin and Regular $+$ NPH Insulin.

METHOD:

In this double-blind, randomized clinical trial study, we enrolled 100 women with GDM as an inpatient. In group A, patients underwent treating with Regular $+$ NPH Insulin, and in group B, patients underwent treating with Novo-rapid $+$ Levemir Insulin. Patient’s demographic and clinical information gathered by specified several times during the study and analysis performed by SPSS21.

RESULTS:

Despite significant changes in the two groups patient’s blood glucose levels; we could not find any remarkable differences between the two groups. In the case of patient and health care system satisfaction and the length of the hospitalization group, B was better than group A.

CONCLUSION:

Altogether, The Novo-rapid and Levemir Insulin in comparing with the Regular and NPH Insulin were practically advantageous due to the simple using method and short hospitalization period of the patient. Thus, we prefer and suggest this beneficial method (using Novo-rapid and Levemir Insulin) to reach therapeutic goals.

Keywords

GDM insulin regular insulin novo-rapid insulin NPH insulin levemir

Get full access to this article

View all access options for this article.

References

Gary Cunningham

K.J.L.F.

Bloom

S.L.

Spong

C.Y.

Dashe

J.S.

Hoffman

B.L.

Casey

B.M.

and Sheffield

J.S.

, in: Williams Obstetrics, New York: McGraw-Hill Education/Medical, 2014, pp. 300–301.

Dornhorst

, Diabetes in pregnancy, Women’s Health Medicine 2 (2005), 8–12.

de Veciana

et al., Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy, N Engl J Med 333 (1995), 1237–1241.

Management of diabetes in pregnancy, Diabetes Care 40 (2017), S114–119.

Balaji

and Seshiah

V.J.J.A.P.I.

, Management of diabetes in pregnancy, Supplement to Japi 59 (2011), 33–36.

Vanhaverbeke

Mertens

Mathieu

, Diabetic management in high risk patients (Pregnancy, Insulin Pumps), Acta Clinica Belgica 59 (2004), 173–181.

Mayo

Melamed

Vandenberghe

Berger

, The impact of adoption of the international association of diabetes in pregnancy study group criteria for the screening and diagnosis of gestational diabetes, American Journal of Obstetrics and Gynecology 212 (2015), e221–229.

Simmons

D.J.C.D.R.

, The utility and efficacy of the new insulins in the management of diabetes and pregnancy, Current Diabetes Reports 2 (2002), 331–336.

Magon

and Chauhan

, Pregnancy in type 1 diabetes mellitus: How special are special issues? North American Journal of Medical Sciences 4 (2012), 250–256.

10.

Getahun

et al., Gestational diabetes in the United States: Temporal trends 1989 through 2004, Am J Obstet Gynecol 198 (2008), e521–525.

11.

Jovanovic

Howard

Pettitt

Zisser

Ospina

, in Diabetologia. (Springer 233 Spring Street, New York, NY 10013 USA, 2005), vol. 48, pp. A317–A318.

12.

Lloyd

et al., Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK, Current Medical Research and Opinion 25 (2009), 599–605.

13.

Jia

and Hu

L.J.B.R.

, Clinical efficacy and safety of novorapid flexpen in treatment of gestational diabetes mellitus, Biomedical Research 28 (2017), 8553–8556.